Superpower vs Hims vs Peptide Clinics for Women Who Want Results

Your skin is thinning, your recovery takes twice as long as it used to, and you've spent enough hours on Reddit threads and group chats to know that peptides like GHK-Cu and BPC-157 are doing real things for women who look like you did five years ago. The problem isn't whether peptides work. The problem is that the provider you pick in 2025 or 2026 determines which compounds you can actually get, what you'll pay, and whether anyone on the other end of the screen treats you like a patient instead of a credit card number.

Right now, Superpower offers the strongest prescriber-led telehealth experience with broader compound access. Hims is building the infrastructure to compete hard on price once the FDA clears the regulatory bottleneck. Traditional peptide clinics remain the deepest option for complex protocols but cost 2 to 4 times more per month. Here's exactly how they stack up on price, selection, prescriber quality, and what's about to change.

Key Takeaways

• Superpower's consultation-plus-subscription model runs roughly $150 to $350/month for a single peptide protocol including prescriber oversight; Hims hasn't published peptide-specific pricing yet but its vertically integrated supply chain positions it as the likely low-cost leader post-FDA vote.
• As of mid-2026, sermorelin, GHK-Cu, and PT-141 are prescribable through 503A compounding. BPC-157, CJC-1295, and ipamorelin sit on the FDA's Category 2 bulks list and face an advisory committee vote on July 23 to 24, 2026.
• Traditional peptide clinics charge $400 to $1,200/month but typically include in-person labs, multi-compound protocols, and more granular monitoring for women managing hormonal interactions.
• The July 2026 FDA advisory committee vote could open a $2.2 billion telehealth peptide market within months, and the provider you choose now determines how fast you get access if compounds clear.
• If you're new to injectable peptides, start with the provider comparison quiz to match your goals, budget, and comfort level to the right model.

---

Why Your Provider Choice Matters More in 2026

Six months ago, picking a peptide provider was mostly about who had the compounds you wanted and whether you trusted the prescriber. That was already complicated. Now it's a moving target.

The FDA's Pharmacy Compounding Advisory Committee is scheduled to vote on July 23 and 24, 2026 on whether seven peptides, including BPC-157 and TB-500, can be legally compounded by 503A pharmacies. That single vote could flip the most sought-after compounds from regulatory gray zone to fully prescribable overnight. Leerink Partners analyst Michael Cherny estimated the peptides under review could support roughly a $2.2 billion annual telehealth market. That's not a niche. That's an industry forming in real time.

Meanwhile, the three provider models (telehealth platforms like Superpower, vertically integrated companies like Hims, and traditional peptide clinics) are all positioning differently for what comes next. Hims acquired a California peptide manufacturing facility in February 2025 and already owns 503A compounding pharmacies in Ohio and Arizona plus a 503B sterile facility. Superpower has been building a prescriber network with documented clinical evaluation protocols. Clinics are doing what they've always done: running labs, writing protocols, and charging a premium for hands-on oversight.

If you're shopping for BPC-157 or GHK-Cu right now, you're making a bet on which model will serve you best in three months, six months, and a year from now. That bet deserves real numbers.

---

How Superpower, Hims, and Peptide Clinics Actually Work

These three models look similar from the outside (you talk to someone, you get peptides) but the internal machinery is completely different, and that machinery determines your experience.

Superpower operates as a prescriber-first telehealth platform. You're matched with a licensed provider who conducts a clinical evaluation, reviews your labs, and writes a prescription that's filled by a partnered 503A compounding pharmacy (a pharmacy licensed to create custom formulations for individual patients based on a prescription). Superpower's published guide on prescription peptides emphasizes that their prescribers should maintain documented rationale for choosing a compounded preparation and a monitoring plan throughout therapy. The model is: the platform connects you to the prescriber, the prescriber connects you to the pharmacy, and the pharmacy ships to you.

Hims (Hims & Hers Health) is vertically integrated, meaning they own the prescriber network, the compounding pharmacies, and now the manufacturing. When you get a prescription through Hims, the compound is made in their own facilities, prescribed by their own providers, and shipped through their own logistics. This is the Costco model applied to telehealth: control every layer, drive the price down, scale fast. The tradeoff is that Hims protocols tend to be more standardized. You're less likely to get a deeply customized protocol and more likely to get a well-priced, well-manufactured version of whatever their formulary includes.

Traditional peptide clinics are in-person or concierge practices run by MDs, DOs, NPs, or PAs who specialize in peptide therapy, often alongside hormone replacement, functional medicine, or anti-aging protocols. They draw their own blood, run their own panels, and write prescriptions filled by 503A pharmacies they've vetted. The prescriber knows your face. The overhead is higher. The depth of monitoring is typically the most thorough of the three models, though quality varies enormously from clinic to clinic.

A quick note on 503A compounding: this refers to pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act, which allows them to compound medications for individual patients with valid prescriptions. PCAB accreditation (from the Pharmacy Compounding Accreditation Board) is an additional quality layer that not all 503A pharmacies carry. Both Superpower and most reputable clinics work with PCAB-accredited pharmacies. Hims controls its own compounding, so the accreditation question is internal to their facilities.

---

Peptide Selection: What Each Provider Can Actually Prescribe Right Now

This is where the comparison gets concrete and where the regulatory moment matters most.

As of mid-2026, the peptides available through any legal prescription route depend on whether the compound is eligible for 503A compounding. Some peptides are clearly available. Others are stuck in the FDA's Category 2 bulks list under the 503A interim policy, meaning their compounding eligibility is under active FDA review.

*Sermorelin's compounding eligibility depends on the pharmacy's API sourcing pathway and USP-NF compliance.

**Some clinics may have existing stock or operate under varying interpretations of the interim policy, but the strict reading is that Category 2 compounds are not supposed to be compounded during the review period.

What this table tells you: right now, the compounds you can get legally prescribed through any of these three models are the same. Superpower, Hims, and clinics all face identical 503A constraints. The difference is that Superpower currently lists more of the available compounds on their formulary, while Hims hasn't fully launched its peptide vertical yet.

The July 23 to 24 vote changes everything. If BPC-157 and the other Category 2 compounds clear the advisory committee, Hims has the manufacturing infrastructure to get product to market fastest. Superpower has the prescriber network ready to write. Clinics have the flexibility but not the scale.

Like most research peptides, injectable GHK-Cu and BPC-157 for gut and healing aren't FDA-approved for the specific uses women are running them for, which is exactly why the interesting real-world evidence lives in what women are actually reporting. Women on GHK-Cu protocols consistently report visible skin texture improvements by week 6 to 8, faster recovery from procedures, and a general "my skin looks like it did at 35" quality that's hard to attribute to anything else when it's the only variable that changed. BPC-157 reports from the community are even more enthusiastic: gut issues resolving in 2 to 4 weeks, joint pain dropping noticeably, and a recovery-from-everything quality that makes women wonder why this isn't the first thing their doctor mentions.

The early data on these compounds is genuinely exciting. GHK-Cu has published research on its role in tissue remodeling, collagen synthesis, and anti-inflammatory signaling (strong mechanistic evidence, small human studies for topical, community-reported results for injectable). BPC-157 has extensive preclinical data showing tissue-protective and healing properties across multiple organ systems, though completed randomized controlled human trials don't exist yet (strong preclinical evidence, mechanism plus anecdote for human use). The absence of big trials here is a function of funding incentives, not a red flag about the compounds themselves. Nobody patents a naturally occurring peptide sequence, so nobody funds a $50 million Phase III trial.

---

Price Breakdown: What You'll Actually Pay Per Month

Nobody's going to tell you peptides are cheap. But the spread between provider models is wide enough that it matters. For a deeper breakdown of what each route actually costs, see our real monthly cost guide.

Superpower's pricing bundles the prescriber relationship into the subscription, which means your per-month cost includes ongoing access to someone who's actually watching your protocol. That's a real difference from paying $200 for a clinic visit every 6 weeks on top of compound costs.

Hims hasn't published final peptide pricing as of this writing (mid-2026), but their structural advantage is obvious. When you own the manufacturing, the compounding pharmacy, and the prescriber network, your margin on each vial is dramatically higher even at a lower sticker price. Their GLP-1 pricing undercut the market by 40 to 60% when they launched that category. Expect a similar move with peptides if the compounds clear.

Clinics are expensive because you're paying for a human who knows your name, draws your blood in person, and adjusts your protocol based on labs they read themselves. For a woman running a complex combination (say, sermorelin plus GHK-Cu plus PT-141 with HRT layered in), that oversight is worth the premium. For a woman who wants a single compound with straightforward monitoring, it's harder to justify $800/month when telehealth gets you to the same place for half.

No one has published pricing for Category 2 peptides yet, because they can't legally compound them. When BPC-157 pricing does appear, the telehealth platforms will almost certainly undercut the clinics by 30 to 50%, and Hims will likely be the price leader.

---

Prescriber Quality and Monitoring: Who Actually Takes Women Seriously

This is the part that matters more than price and more than selection, because a bad prescriber with the right compound is worse than no prescriber at all.

Women's experience with peptide providers falls into a pattern that's depressingly familiar if you've ever tried to get HRT, get your thyroid taken seriously, or get anyone in a white coat to acknowledge that your symptoms are real. You know what you want, you've done the research, and the provider either listens or doesn't.

What a good prescriber does before writing your first peptide prescription:

They run baseline labs. At minimum, that's a comprehensive metabolic panel (CMP), complete blood count (CBC), fasting insulin, IGF-1 (if you're going on a growth hormone secretagogue), and a hormone panel if you're on or considering HRT. A thorough prescriber also checks liver and kidney function markers because peptides are metabolized through those pathways, and some compounds (particularly at higher doses) can affect hepatic enzymes. If you're not sure what to order, our bloodwork-before-peptides guide covers the full panel.

They ask about your cycle. Injectable peptides interact with your hormonal environment. A prescriber who doesn't ask where you are in your menstrual cycle, whether you're perimenopausal, whether you're on HRT, or whether pregnancy is even a remote possibility is not paying attention. PT-141 (bremelanotide), for example, is contraindicated in pregnancy and should be used with caution in women with uncontrolled hypertension.

They have a monitoring plan. Follow-up labs at 6 to 8 weeks, a check-in on side effects, and a willingness to adjust dose or compound based on what your body is doing, not what the protocol sheet says.

How each model performs on these criteria:

Superpower's published framework explicitly names full clinical evaluation, baseline lab review, documented rationale for compounded preparations, and ongoing monitoring as standards for their prescriber network. In practice, women report that Superpower prescribers tend to ask more questions upfront and are more willing to discuss compound selection as a conversation rather than a menu pick. The telehealth format means you're not getting blood drawn through the platform (you'll go to a local lab or use an at-home kit), but the prescriber reviews the results before writing anything.

Hims scales through standardized protocols, which means your provider is working from a decision tree optimized for efficiency. This works well for straightforward, single-compound use cases. It works less well if you're a 47-year-old woman on estradiol and progesterone who wants to add sermorelin and GHK-Cu and needs someone to think about how those layers interact. Hims's strength is accessibility and speed. Their weakness, based on community reports from women who've used the platform for other categories (GLP-1s, hair loss), is that the providers sometimes feel like they're checking boxes rather than listening.

Traditional clinics are the most variable. The best ones are extraordinary: a provider who's been prescribing peptides for 5+ years, knows the literature cold, draws your blood in the office, calls you when your IGF-1 comes back high, and adjusts your protocol the same week. The worst ones are cash-grab operations that prescribe whatever you ask for, skip labs, and see you as a recurring revenue line. There's no accreditation body for "peptide clinic quality," so you're relying on reputation, referrals, and your own gut feeling in the first visit. Our guide on which doctors prescribe peptides covers what to look for and what to ask.

What to ask any provider before you start:

1. What baseline labs do you require, and what are you looking for in the results?
2. How do you adjust protocols for women on HRT or in perimenopause?
3. What's your monitoring schedule, and what labs do you re-run at follow-up?
4. Which 503A pharmacy fills your prescriptions, and is it PCAB-accredited?
5. If I have a side effect at 10pm on a Tuesday, how do I reach someone?

The answers to those five questions will tell you more about your provider than their website ever will.

---

The Regulatory Moment That Could Change Everything by Year-End

On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee will review seven peptides for possible addition to the list of bulk drug substances that 503A pharmacies can legally compound. BPC-157 and TB-500 are on the agenda. This is the vote the entire peptide telehealth industry has been building toward.

If the committee votes favorably, here's what happens in practical terms:

503A pharmacies can begin compounding BPC-157, TB-500, and potentially CJC-1295 and ipamorelin for individual prescriptions. Telehealth platforms with existing prescriber networks and pharmacy relationships (Superpower, Hims) can begin offering these compounds within weeks, not months. The $2.2 billion market estimate that analysts have been circulating becomes a real number with real revenue behind it.

Hims is positioned to move fastest. They own the manufacturing. They own the pharmacies. They own the prescriber network. When the regulatory gate opens, they don't need to negotiate a single new partnership. They flip a switch. Analysts at Leerink estimated Hims could capture roughly 20% of that $2.2 billion market.

Superpower is positioned to move with more clinical depth. Their prescriber network is already trained on peptide protocols, and their pharmacy partnerships are established. They won't manufacture the compounds themselves, but they can prescribe and fulfill faster than a traditional clinic can onboard new patients.

Traditional clinics will benefit from the expanded formulary but won't see the same scale effects. A clinic that currently sees 200 patients can't suddenly see 2,000. Their advantage remains depth of care, not speed of access.

If the committee votes unfavorably, or defers (which is also possible), the status quo holds. Category 2 compounds remain in limbo. The telehealth platforms keep building infrastructure for a day that hasn't arrived yet. And women who want BPC-157 continue to exist in the space between "this compound clearly does something" and "the regulatory framework hasn't caught up."

The analyst consensus, per Fortune's reporting on the vote, is that well-funded platforms will consolidate smaller players within six months of a favorable vote. If you're choosing a provider now, you're choosing one that will either be a consolidator or get consolidated.

---

Which Provider Fits Your Situation

Your best option depends on three things: what compound you want, how much oversight you need, and what you're willing to spend.

A few practical notes on timing. If you're interested in compounds currently on the Category 2 list (BPC-157, CJC-1295, ipamorelin, TB-500), the smartest move right now is to establish a relationship with a telehealth provider before the July vote. Get your consultation done. Get your labs run. Be a patient in the system. If the vote goes favorably, you'll be able to get a prescription filled weeks before someone who starts from scratch in August.

If you're interested in compounds that are available today (GHK-Cu for skin and tissue repair, sermorelin for growth hormone support, PT-141 for sexual function), you don't need to wait for anything. These are prescribable now through both Superpower and most peptide clinics.

If you're not sure which compounds match your goals, or which provider model fits your life, build your personal plan to get a recommendation based on your budget, your goals, and how much hand-holding you actually want.

---

Frequently Asked Questions

Is Superpower legit for prescription peptides? Yes. Superpower operates as a telehealth platform connecting patients with licensed prescribers who write prescriptions filled by 503A compounding pharmacies. Their published clinical framework includes baseline labs, documented rationale for compounded preparations, and monitoring plans. They're not a pharmacy themselves; they're the prescriber layer.

Does Hims actually prescribe peptides to women, or is it mostly for men? Hims & Hers Health serves both men and women (the "Hers" side of the brand). Their peptide category hasn't fully launched as of mid-2026, but their existing categories (GLP-1s, hair loss, skincare) serve women extensively. When peptide prescribing goes live, women will have equal access through the platform.

Can I get BPC-157 prescribed legally right now? As of mid-2026, BPC-157 is on the FDA's Category 2 bulks list, meaning its eligibility for 503A compounding is under active review. The advisory committee vote on July 23 to 24, 2026 will determine whether it can be legally compounded. Until that vote, BPC-157 is not supposed to be compounded under the interim policy.

What's the difference between a 503A compounding pharmacy and buying peptides online? A 503A pharmacy is a licensed facility that compounds medications for individual patients based on valid prescriptions from licensed providers. It operates under federal and state pharmacy law, with oversight and inspections. The prescription route means a provider has evaluated you, ordered labs, and determined the compound is appropriate for your situation.

How much should I expect to pay per month for a peptide protocol? For a single compound through telehealth (Superpower), expect $150 to $350/month including consultation and the compound. Through a traditional clinic, $400 to $800/month for a single compound with in-person labs and monitoring. Multi-compound protocols through clinics can run $800 to $1,200/month. Hims pricing hasn't been published but is expected to undercut telehealth competitors by 30 to 50% based on their cost structure.

Do I need lab work before starting peptides? Any provider worth trusting will require baseline labs. At minimum: comprehensive metabolic panel, complete blood count, and IGF-1 if you're starting a growth hormone secretagogue. If you're on HRT or in perimenopause, a hormone panel is standard. Labs protect you by establishing a baseline so your provider can spot changes at your 6 to 8 week follow-up.

What happens to my peptide prescription if the FDA votes against compounding BPC-157? If the advisory committee votes unfavorably, BPC-157 remains on the Category 2 list and 503A pharmacies cannot compound it under the interim policy. Any existing prescriptions would not be fillable. Compounds that are currently available (sermorelin, GHK-Cu, PT-141) would be unaffected by a negative vote on BPC-157 specifically.

Are peptide clinics worth the higher price compared to telehealth? It depends on your protocol complexity. If you're running multiple compounds alongside HRT, want in-person blood draws, and value a provider who adjusts your protocol based on labs they've read that morning, a clinic is worth $400 to $800/month. If you want a single compound with competent telehealth oversight, you're paying a premium for proximity you may not need.

Which peptides are actually available for women through telehealth right now? As of mid-2026: sermorelin (growth hormone secretagogue), GHK-Cu (skin and tissue repair peptide), and PT-141/bremelanotide (sexual function) are the most commonly prescribed through telehealth platforms like Superpower. Availability of specific compounds varies by the platform's pharmacy partnerships and formulary.

How do I know if my peptide provider is using a PCAB-accredited pharmacy? Ask them directly. "Which 503A pharmacy fills your prescriptions, and is it PCAB-accredited?" is a reasonable question, and any provider who bristles at it is telling you something. PCAB accreditation (from the Pharmacy Compounding Accreditation Board) means the pharmacy has met additional quality standards beyond state licensing requirements. Superpower's framework specifically names PCAB-accredited pharmacy partnerships as a standard.